GlassScriptPhysician profile
Diane Dodgen
NPI 1134117385
$1,401.59
in general payments reported to CMS, 2019-2025
21 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $485 · 2020: $598 · 2021: $276 · 2022: $26.79 · 2023: $16.15.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $16.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $16.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $177.39 | 2019-2021 | |
| Novo Nordisk INC | $141.92 | 2019-2020 | |
| Pfizer INC. | $141.02 | 2019-2021 | |
| Amarin Pharma, INC. | $123.01 | 2019-2021 | |
| Lilly USA, LLC | $116.83 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $86.37 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $84.31 | 2019 | |
| Janssen Pharmaceuticals, INC | $67.10 | 2019-2021 | |
| Eisai INC. | $64.43 | 2020 | |
| Supernus Pharmaceuticals, INC. | $61.20 | 2019 | |
| Jazz Pharmaceuticals INC. | $53.93 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $51.64 | 2019-2021 | |
| Amgen INC. | $42.94 | 2022-2023 | Otezla, Repatha |
| Allergan, INC. | $36.82 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $30.67 | 2019-2020 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Melinta Therapeutics, LLC | $29.50 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $27.65 | 2019-2021 | |
| Glaxosmithkline, LLC. | $20.15 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.79 | 2021 | |
| Ironshore Pharmaceuticals INC. | $15.36 | 2019 | |
| Pbg Puerto Rico LLC | $11.56 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Diane Dodgen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.